India regulates medical devices and in-vitro diagnostics (IVDs) under the Medical Devices Rules 2017, administered by the Central Drugs Standard Control Organisation (CDSCO). Since the rules were extended to cover all medical devices, every manufacturer and importer needs a defined regulatory pathway to place products on the Indian market legally. This guide walks through classification, the license types, the documentation, and the realities of timelines.
The regulatory framework in brief
The Medical Devices Rules 2017 (MDR 2017), made under the Drugs and Cosmetics Act, moved India from regulating a short list of notified devices to a comprehensive, risk based system covering all medical devices and IVDs. CDSCO acts as the Central Licensing Authority, State Licensing Authorities handle lower risk domestic manufacturing, and applications flow through the online SUGAM portal. The rules borrow recognizably from the Global Harmonization Task Force framework, so manufacturers familiar with EU or ASEAN classification logic will find the structure familiar, though the details are India specific.
Risk classification: Class A to Class D
- Class A, low risk: items such as absorbent cotton, surgical dressings, and many non-sterile instruments.
- Class B, low moderate risk: devices such as hypodermic needles and suction equipment.
- Class C, moderate high risk: devices such as bone fixation plates, ventilators, and implants with medium duration body contact.
- Class D, high risk: devices such as heart valves, drug eluting stents, and high individual risk IVDs.
Classification determines everything downstream: which authority licenses the product, what evidence is expected, and how long review takes. CDSCO publishes classification lists by device category, and checking your device against the published classification before planning the submission prevents the most common early error, which is preparing the wrong application entirely. Class A devices that are non-sterile and non-measuring follow a simplified registration route with significantly lighter requirements.
Which license you need
Manufacturing in India
- Class A and B: manufacturing license MD-5 (application form MD-3), granted by the State Licensing Authority, with Class A non-sterile non-measuring devices handled through the simplified registration pathway.
- Class C and D: manufacturing license MD-9 (application form MD-7), granted by the Central Licensing Authority.
Importing into India
All import licensing is central. The importer applies for an MD-15 import license using form MD-14 through an Authorized Indian Agent, a legal entity in India that holds the license and takes regulatory responsibility. Foreign manufacturers without an Indian subsidiary must appoint one, and choosing that agent is a strategic decision, since the license is tied to them.
Supporting licenses
A test license (MD-13, application MD-12) covers importing or manufacturing devices for evaluation, demonstration, or clinical investigation before full licensing. Clinical investigations of investigational devices require separate approval under the rules, with requirements scaled to device risk.
The documentation that decides your review
- Device Master File: the technical core, covering device description, intended use, design, specifications, risk analysis, verification and validation evidence, stability, and labeling.
- Plant Master File: the manufacturing site, its quality system, and its capabilities.
- Quality management system certification: ISO 13485 certification is the expected baseline for the manufacturing site.
- Evidence of foreign approval: for imports, a Free Sale Certificate and approval evidence from regulators such as the US FDA, EU notified bodies, TGA, Health Canada, or PMDA materially smooth review, and devices approved in those jurisdictions can benefit from reduced scrutiny.
- Clinical evidence: scaled to class, from literature based justification for lower classes to clinical investigation data for novel high risk devices, with predicate device comparison playing a central role where a comparable device is already marketed in India.
- Labeling: compliant with the rules' labeling chapter, including Indian import license details and units.
Timelines, fees, and honest expectations
Statutory processing targets exist, but real world timelines depend on classification, application completeness, and query cycles. As working planning figures, simplified Class A registrations move fastest, MD-5 state licenses commonly complete within a few months, and MD-15 import licenses for Class C and D devices typically take six to nine months including query rounds. Fees are set per device or device family and per site, published in the rules' fee schedule, and modest by international standards; the real cost of the process is time, and the largest avoidable delays come from incomplete Device Master Files and slow query responses. Licenses granted under MDR 2017 remain valid perpetually subject to payment of a retention fee every five years, which removes the renewal cliff that older frameworks had.
IVDs under the same rules, with their own logic
In-vitro diagnostics are regulated within MDR 2017 through the same license architecture but their own classification annex, again from Class A to Class D by individual and public health risk. High individual risk assays such as blood screening tests sit in Class D, while general laboratory reagents sit lower. Performance evaluation carries the evidential weight for IVDs: analytical performance (accuracy, precision, analytical sensitivity and specificity, interference) and clinical performance appropriate to the intended use, with Indian population applicability considered where relevant. Manufacturers preparing IVDR performance evaluation files for Europe will find substantial reuse potential, and structuring the evidence once for both markets is materially cheaper than writing twice.
After the license: the obligations that continue
Grant of an MD-15 or MD-9 license is the start of ongoing obligations, not the end of the process. License holders must maintain post-market surveillance, report serious adverse events to CDSCO within the required timelines under the Materiovigilance Programme of India, and manage changes properly: significant changes to the device, its labeling, or its manufacturing site require prior approval or notification depending on the change category, and shipping a changed device under an unchanged license is a compliance breach inspectors specifically look for. Periodic safety update obligations, record keeping, and the five yearly retention fee complete the picture. Companies that assign clear internal ownership of these duties at grant avoid the scramble that otherwise happens at the first audit or adverse event.
Where applications go wrong
- Misclassification discovered mid review, restarting the pathway.
- Device Master Files assembled from marketing materials rather than design documentation, triggering long query chains.
- Free Sale Certificates that do not match the exact device variants applied for.
- Authorized agent arrangements agreed commercially but documented incorrectly for the license.
- Labeling artwork finalized before Indian requirements were checked.
How EvySaif supports CDSCO registrations
EvySaif prepares classification assessments, Device and Plant Master Files, clinical evidence justifications, and complete MD-14 and MD-3 or MD-7 applications, and manages query responses through grant. Because the same team writes clinical evaluation reports and EU technical documentation, evidence prepared for one market is reused intelligently for the other. See our CDSCO registration services or discuss your device pathway with us.